GlassScriptPhysician profile
Katherine Mcgovern
NPI 1336800606
$1,562.04
in general payments reported to CMS, 2019-2025
16 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $297 · 2023: $227 · 2024: $806 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $665.30 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $190.95 | 2023-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.57 | 2024-2025 | Relistor |
| Nevro Corp. | $96.26 | 2024 | Senza |
| Pfizer INC. | $71.07 | 2024-2025 | |
| Scilex Pharmaceuticals INC. | $58.39 | 2022-2025 | Ztlido |
| Vanda Pharmaceuticals INC. | $55.00 | 2024 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $38.99 | 2024 | Trintellix |
| Tris Pharma INC | $38.39 | 2024 | Dyanavel Xr |
| Globus Medical, INC. | $31.61 | 2025 | Senza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.49 | 2024-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $26.02 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $22.09 | 2025 | |
| Idorsia Pharmaceuticals US INC | $16.45 | 2024 | Quviviq |
| Ibsa Pharma INC. | $16.40 | 2023 | Tirosint, Licart |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $14.06 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Mcgovern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.